ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1032

Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis

Katarzyna Matyja1,2, Matthieu Ribon1,2, Roxane Hervé1,2, Delphine Lemeiter1,2, Ken Tsumiyama3, Natacha Bessis1,2, Shunichi Shiozawa3, Marie-Christophe Boissier1,2,4 and Patrice Decker1,2, 1Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, 2UMR 1125, Inserm, Bobigny, France, 3Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, 4Rheumatology Department, Assistance Publique – Hôpitaux de Paris (AP-HP), Avicenne Hospital, Bobigny, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Animal models, Interferons and rheumatoid arthritis, T-Regulatory Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Animal Models I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The role of IFN-I is also controversial in rheumatoid arthritis (RA) and experimental models. An IFN-I signature has been reported in RA patients, the signification of which is unclear. In mice, IFN-I enhance or inhibit arthritis development according to the IFN subtype, arthritis model and the kinetics. Because of the reported IFN-I/TNF cross-regulation, and TNF being a key pathogenic cytokine in RA, we have evaluated the therapeutic effect of early IFN-α production in collagen-induced arthritis (CIA).

Methods:  CIA was induced by 2 immunizations with collagen/CFA. Disease development was studied in conditional transgenic mice over-expressing mouse IFN-α1 after cessation of doxycyclin (Dox) administration (Tet-off system). IFN-α1-negative littermates were used as controls. All mice express endogenous IFN-α. All mice were treated with Dox. Arthritis was followed by clinical evaluation. Inflammation/bone destruction were estimated by histology. Plasma cytokines and anti-collagen antibodies were measured by Luminex/ELISA. Leukocytes sub-populations and Th1/Th2/Th17 polarization were analyzed by flow cytometry. Bone marrow cells were cultured with M-CSF/RANKL to evaluate osteoclast differentiation and activity. CD4+CD25+ regulatory T cells (Treg) and CD4+CD25– effector T cells (Teff) were purified by magnetic sorting. Treg ATPase activity was determined in vitro by a luminescent assay. Treg inhibition of Teff proliferation/activation was measured by flow cytometry/ELISA in co-cultures. The in vivo therapeutic capacity of purified Treg was estimated by adoptive transfer.

Results:  Induction of mouse IFN-α1 production before the first or even before the second immunization resulted in CIA protection. Both immunized IFN-α1– and IFN-α1+ mice produced anti-collagen antibodies, however the latter produced less. Likewise, IFN-α1+ mice produced less IL-6 but more IL-5. Protection was associated with decreased polarization to Th17 and increased polarization to Th1 and Th2 lymphocytes. Moreover, IFN-α1+ mice showed increased levels of IFN-γ-positive NK cells. On the contrary, osteoclastogenesis and osteoclast activity were decreased in IFN-α1+ mice. Particularly, CIA protection in IFN-α1-overexpressing mice was associated with an expansion of Treg with a higher CD39 expression, higher ATPase activity and a higher capacity to inhibit Teff. Most importantly, adoptive transfer of those highly suppressive Treg purified from CIA IFN-α1+ mice impaired CIA development in recipients in comparison to adoptive transfer of Treg purified from CIA IFN-α1– mice.

Conclusion:  This is the first study analyzing the impact of IFN-α on CIA development. Induction of IFN-α1 production before immunization or even after the first immunization nearly completely protects against arthritis. Protection is associated with an expansion of more suppressive Treg able to confer protection upon adoptive transfer. This work better defines the role of IFN-α and shows its potent modulatory effect in inflammatory arthritis.


Disclosure: K. Matyja, None; M. Ribon, None; R. Hervé, None; D. Lemeiter, None; K. Tsumiyama, None; N. Bessis, None; S. Shiozawa, None; M. C. Boissier, None; P. Decker, None.

To cite this abstract in AMA style:

Matyja K, Ribon M, Hervé R, Lemeiter D, Tsumiyama K, Bessis N, Shiozawa S, Boissier MC, Decker P. Early In Vivo Induction of Mouse Interferon-alpha1 Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/early-in-vivo-induction-of-mouse-interferon-alpha1-overexpression-triggers-an-expansion-of-highly-suppressive-regulatory-t-lymphocytes-protecting-against-experimental-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-in-vivo-induction-of-mouse-interferon-alpha1-overexpression-triggers-an-expansion-of-highly-suppressive-regulatory-t-lymphocytes-protecting-against-experimental-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology